Skip to content

Join A New Clinical Trial for Untreated Parkinson's

Are you in the early stages of Parkinson's disease and seeking a transformative treatment? Join our groundbreaking Phase 2 clinical trial and become a vital participant in pioneering research that has the potential to slow or stop Parkinson's disease progression. 

Senior couple in convertible car enjoying day trip
OPEN CLINICAL TRIAL

Help us achieve a breakthrough with Inhibikase's most advanced therapeutic candidate, IkT-148009, treatment for untreated patients with Parkinson's Disease.

Discover New Hope. Join Our Clinical Trial.

SC3 Research Group, Inc.

Be a Hero in the Fight Against Parkinson's

Sign Up Now to Join the Clinical Trial!

Ready to be a part of the future of Parkinson's treatment? Take the first step by signing up for our groundbreaking clinical trial today.

Get in Touch

Attractive young woman working on a desktop computer smiling as she leans forwards reading text on the screen, view over the monitor

Note: A dedicated study member will call you within 24 hours to initiate the pre-screening process and provide further details. Don't miss out on this opportunity! Join now and make a lasting impact in the fight against Parkinson's disease.

Sign up today to join.


Points of contact

SC3 Research Group, Inc.

19231 Victory Blvd., Ste. 351, Reseda, CA, 91335 USA

Roxanne Cabading
Patient Engagement

 (626) 250-2070 

About the Study

First-in-class Therapy to Reverse the Course of Parkinson’s Disease

We're investigating the safety and potential of IkT-148009. IkT-148009 is a new Abl kinase inhibitor that could block the checkpoint and slow or stop Parkinson's disease progression.   

What Will the Study Measure?

Your health, safety, and well-being are our top priorities. We're dedicated to evaluating the safety and tolerability of IkT-148009, ensuring that it's not only effective but also gentle and well-tolerated. Throughout the 18-week duration of the study, we'll  also  assess both your motor abilities—how you move—and the non-motor symptoms that impact your daily life.

Parkinson's patients who are not currently taking antiparkinsonian medicines

Not currently taking levodopa or dopamine agonists to manage symptoms or have taken antiparkinsonian therapy for less than 28 days

About Parkinson's Disease

Parkinson’s disease develops when neurons that produce the neurotransmitter dopamine begin to die or lose function. Loss of these and other neurons leads to involuntary tremors, slow and imprecise movements, muscle stiffness, postural instability, loss of memory and dysfunction of the GI tract. All marketed therapeutic approaches to treat Parkinson’s help manage the symptoms of the disease, but there are currently no available treatments to slow or stop the disease’s relentless progression.

The underlying causes of neural death in Parkinson’s disease are beginning to be understood. Abl kinases have been shown to play a critical role in monitoring insults to neurons inside and outside of the brain and regulating biochemical pathways that are responsible for protecting neurons from dying or losing function in the brain and other areas of the body. In addition, recent research has demonstrated that Abl kinases are essential checkpoint regulators that play a central role in Parkinson’s disease progression.

Study Participation Overview

Study participation will take approximately 35 weeks

Screening Period

Up to 31 days

The study doctor and study staff will review your medical history and conduct a number of tests and assessments to determine if you are fully eligible to participate. This visit will last approximately four hours.

Study Treatment Period

18 weeks

You will begin taking your assigned study drug (investigational drug or placebo) as directed by the study doctor. You will be asked to attend 6 study visits where you will take part in study-related tests and assessments to monitor your health and the effects (if any) of your assigned study drug. These visits are expected to last approximately one to two hours.

Safety Follow-up Period

Up to 30 days after your final study visit

A member of the study team will contact you by phone for a final check-in.

Why participate in this clinical trial

Eligible study participants will receive the following at no cost:

If you decide to join the study, your health and safety will carefully be monitored by specialists, and your participation will help doctors evaluate the study drugs to measure it's effectivity. 

Study-related consultation and care

Study visits, tests, assessments, and procedures

Study drugs (investigational drug or placebo)

Am I eligible?

You may be eligible to participate if you meet the following eligibility criteria:

Doctor listening to a patient at her practice

Have been diagnosed with PD

Receiving no anti-parkinsonian therapy

30 to 75 years of age

To participate in this study, you must meet the age requirements.

Experiencing bradykinesia

slowness of movement

Experiencing motor asymmetry

impairment in mobility, coordination

Be a Hero in the Fight Against Parkinson's

Sign Up Now to Join the Clinical Trial!

Ready to be a part of the future of Parkinson's treatment? Take the first step by signing up for our groundbreaking clinical trial today.

Get in Touch

Attractive young woman working on a desktop computer smiling as she leans forwards reading text on the screen, view over the monitor

Note: A dedicated study member will call you within 24 hours to initiate the pre-screening process and provide further details. Don't miss out on this opportunity! Join now and make a lasting impact in the fight against Parkinson's disease.

Sign up today to join.


Points of contact

SC3 Research Group, Inc.

19231 Victory Blvd., Ste. 351, Reseda, CA, 91335 USA

Roxanne Cabading
Patient Engagement

 (626) 250-2070 

About SC3 Research Group, Inc.

research

At SC3 Research, our goal is to advance the discovery of treatments for neurodegenerative disorders.  Our website provides you the latest information on actively recruiting clinical research trials at our Pasadena and Reseda clinics.

PRIMARY OBJECTIVE

Portrait of confident happy group of doctors standing at the medical office

With clinic locations in Pasadena, Reseda, and Beverly Grove, SC3 Research has a team of dedicated and experienced investigators, raters, clinical research coordinators, and support staff to ensure the safety of study participants and the integrity of study data.

OUR EXPERTISE